Drug maker Boehringer Ingelheim inaugurated its new biopharmaceutical production facility in Vienna, Austria this month, marking the completion of the €700 million (about $807 million) project. The company said the Large Scale Cell Culture (LSCC) site was its largest-ever investment.
“The potential of biopharmaceuticals for future innovative treatments is growing fast. We are committed to investing in the development of additional production platforms for biologics based on the latest technologies,” Hubertus von Baumbach, chair of the firm’s Board of Managing Directors, said in a company release. “There are still many patients today whose diseases cannot be adequately treated. That is why we are putting every effort into advancing the science that will enable us to achieve the next medical breakthrough.”
Several fermenters were installed with a combined 185,000 L of capacity. The facility features a design that enables Boehringer Ingelheim to quickly change from one product to another and simultaneously produce various products.
“With our facilities set up as multi-product plants and flexible line structures, we are able to supply a variety of molecule formats, such as monoclonal antibodies, enzymes, cytokines, and other recombinant proteins for patients with unmet medical needs,” said Uwe Beucheler, head of the Pharmaceuticals business unit, in a statement.